Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

European Medical Information Framework

EMIF

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information...

Funding Programme
Start Date
End Date
Total Funding
€ 53 642 677

European Patient Organizations in Knowledge Society

EPOKS

The last two decades have witnessed the increasing role of patient, user and civil society organizations (POs and CSOs) in the production of knowledge on diseases and health problems. Rich and detailed studies have shown that this phenomenon entails new forms of activism. It also questions the modes of governance of knowledge, as well as the role...

Funding Programme
Start Date
End Date
Total Funding
€ 1 129 013
European Countries Involved

European Prevention of Alzheimer’s Dementia Consortium

EPAD

The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions.

To achieve this, EPAD...

Funding Programme
Start Date
End Date
Total Funding
€ 53 237 842

European Quality In Preclinical Data

EQIPD

Pharmaceutical industry, as well as basic science, depend on robust data and scientific rigor as key drivers for decision making, patent strength and time-to-market, which in turn will determine knowledge gain and availability of new treatments to patients. Recent publications report challenges with the robustness, rigor, and/or validity of...

Funding Programme
Start Date
End Date
Total Funding
€ 9 845 484
European Countries Involved

EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances

EURIPIDES

'We aim develop in-vivo imaging biomarker of multidrug transporter function as a generic tool for the prediction, diagnosis, monitoring and prognosis of major CNS diseases, as well as to provide support and guidance for therapeutic interventions. Multidrug transporters actively transport substrates (including multiple CNS drugs) against...

Funding Programme
Start Date
End Date
Total Funding
€ 9 086 523
European Countries Involved

Exploring glycosidic neo-epitopes of degenerative hippocampal granules in aged mice and humans: implications for ageing and dementia

GLYCONEOBRAIN

Ageing is the main correlate of dementia and several other neurodegenerative diseases which currently affect more than 6 million people in Europe. Molecular understanding of these brain conditions is important for their prevention and treatment. In mice, pathological granular structures positive for periodic acid-Schiff stain have been found in the...

Funding Programme
Start Date
End Date
Total Funding
€ 183 455
European Countries Involved

Fast transformation between episodic and semantic memories: Interactions between the hippocampal formation and related regions and their breakdown in Alzheimer’s disease

TRANSMEM

'Our memories define who we are and allow us to live independently. Conscious memory is commonly split into two components; “episodic memory” for events that are specific in time and place, and “semantic memory” for our conceptual knowledge about the world. The acquisition of both episodic and semantic memories depends upon the hippocampal...

Funding Programme
Start Date
End Date
Total Funding
€ 1 169 788
European Countries Involved

First Closed-loop non-Invasive Seizure Prevention System

RELIEVE

The goal of Project RELIEVE is to build the very first non-invasive effective closed-loop monitoring and intervention system for brain-related disorders. The outcomes can be used to treat or manage various psychiatric and neurological disorders. We do this by pushing the technological boundaries in two separate domains. (1) AI domain: We develop a...

Funding Programme
Start Date
End Date
Total Funding
€ 2 809 260
European Countries Involved

FROM PATIENT DATA TO PERSONALISED HEALTHCARE IN ALZHEIMER'S DISEASE

PredictAD

Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades. Alzheimer's disease (AD) covers 60-70% of all dementia cases. No...

Funding Programme
Start Date
End Date
Total Funding
€ 3 908 233
European Countries Involved

Gene Editing as Therapeutic Strategy for C9ORF72 Linked ALS/FTD

CORFEDITING

Expansion of a hexanucleotide repeat G4C2 in the non-coding region of chromosome 9 open reading frame 72 (C9orf72) is the most common genetic cause for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). ALS is a fatal condition characterized by progressive motor deficits, degeneration of upper and lower motor neurons (MNs) and...

Funding Programme
Start Date
End Date
Total Funding
€ 149 995
European Countries Involved

Generalised EMF Research using Novel Methods – an integrated approach: from research to risk assessment and support to risk management

GERONIMO

The EU population is increasingly exposed to new physical and chemical agents in the environment, some of which may be detrimental to public health. Of these, electromagnetic fields (EMF) are one of the most ubiquitous, with new EMF technologies and novel applications being actively developed and commercialised. To address pertinent questions on...

Funding Programme
Start Date
End Date
Total Funding
€ 7 853 407

Genomic Instability in Alzheimer’s Disease and Related Disorders: a Single-Cell Approach

INSTALZ

Increasing evidence suggests that the genetic information in our bodies can vary from cell to cell. Such variation has also been found in the brain, although its consequences for brain function or disease remain largely unknown. In this project, we will study the role of genomic instability in Alzheimer's disease and related tauopathies. The...

Funding Programme
Start Date
End Date
Total Funding
€ 1 837 608
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).